Form 4: Inozyme Pharma Director Axel Bolte Acquires 28,000 Stock Options

Director Axel Bolte acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024.

Summary

• On June 18, 2024, Axel Bolte, a director of Inozyme Pharma, Inc., was granted 28,000 stock options.
• The exercise price of these options is $4.4.
• The options vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.
• The options expire on June 17, 2034.
• Following the transaction, Bolte directly owns 28,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices. The grant of options aligns director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparing the size of the grant to similar companies would require further analysis of Inozyme Pharma's compensation policies and market capitalization.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates